Cautious optimism for the antibacterial pipeline: Despite dire warnings, there is resurgent effort to develop novel antibiotics, with several dozen candidate drugs already entered into clinical trials

Microbe

Volumn 9, Issue 4, 2014, Pages 147-152

  Pucci, Michael J ^a   Page, Malcolm G P ^b   Bush, Karen ^c  

^a Pharmaceuticals   (United States)

^b BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84898712621     PISSN: 15587452     EISSN: 15587460     Source Type: Journal    
DOI: 10.1128/microbe.9.147.1     Document Type: Article

References (5)

1. Boucher, H. W., G. H. Talbot, D. K. Benjamin, J. Bradley, R. J. Guidos, R. N. Jones, B. E. Murray, R. A. Bonomo and D. Gilbert. 2013. 10 '20 Progress- development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56:1685-1694.
2. Butler, M. S., M. A. Blaskovich and M. A. Cooper. 2013. Antibiotics in the clinical pipeline in 2013. J. Antibiotics 66:571-591.
3. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States. 2013. U. S. Department of Health and Human Services.
4. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. www.clinicaltrials.gov
5. Pucci, M. J. and K. Bush. 2013. Investigational antimicrobial agents of 2013. Clin. Microbiol. Rev. 26: 792-821.